AUG 24, 2021 8:00 AM PDT

A comparison of drugs for relapsing-remitting multiple sclerosis.

WRITTEN BY: J. Bryce Ortiz

Multiple sclerosis (MS) is a rare and unpredictable autoimmune disease in which the body’s innate immune system attacks cells of the nervous system and breaks down the communication between nerve cells. The best current estimates show that nearly 1 million people in the United States are living with MS. The disease course of MS is unpredictable, and the cause is still unknown, but many individuals with MS may live symptom free for most of their lives. However, in some individuals debilitating symptoms may develop which include numbness or weakness of limbs, tremors, vision problems, fatigue, and problems with bowel and bladder function.  

While there is no cure for MS, treatment focuses on modifying the progression of the disease and targets the immune system to prevent nerve damage. And while several disease modifying treatments exists, most patients with MS have a relapsing-remitting disease course. This means that the patient will experience periods of new MS-related symptoms (or relapses) that improve partially or completely for periods of time, and the disease enters a remission phase for months or years. In a recent study published in Frontiers in Neurology, researchers investigated the long-term efficacy of two drugs that are used for patients with highly active relapsing-remitting MS. 

As discussed in the video, Natalizumab has been a treatment for relapsing-remitting MS for the past 16 years. Additionally, fingolimod is another approved treatment for the disease. However, no study has directly compared the two drugs in terms of efficacy in patients after long-term use. In their study, the researchers compared patients who have taken either drug and compared time to disability improvement and time to disability worsening. It was found that the drug Natalizumab was superior to the other drug in terms of relapse to MS symptoms and other markers as determined by brain scans. As such, the drug is more beneficial to MS patients and provides relief from symptoms and improves the lives of patients. 

 

Sources: Mayo ClinicFrontiers in Neurology

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
JUL 22, 2021
Drug Discovery & Development
Enhancing Myelin to Treat Alzheimer's Disease
JUL 22, 2021
Enhancing Myelin to Treat Alzheimer's Disease
Brain cells, or neurons, communicate through electrochemical signals. The electrical signals travel down a neuron’ ...
AUG 15, 2021
Drug Discovery & Development
Diabetes Drug May Reduce Alzheimer's Risk
AUG 15, 2021
Diabetes Drug May Reduce Alzheimer's Risk
People who take a drug used to lower blood sugar levels in type 2 diabetes have less amyloid-beta in their brains, a bio ...
AUG 21, 2021
Drug Discovery & Development
Schools of Fish Inspire 'Microswimmers' that Could Revolutionize Drug Delivery
AUG 21, 2021
Schools of Fish Inspire 'Microswimmers' that Could Revolutionize Drug Delivery
When 'microswimmers'- microscopic objects that can move in liquid environments- move in the same direction insid ...
SEP 07, 2021
Health & Medicine
Vaccines- a Long History of Cost-Benefit Analysis
SEP 07, 2021
Vaccines- a Long History of Cost-Benefit Analysis
Vaccination and new treatments for diseases have remained topics of skepticism since their inception. When it came to an ...
OCT 05, 2021
Drug Discovery & Development
Drug repurposing for COVID-19
OCT 05, 2021
Drug repurposing for COVID-19
The coronavirus disease that began in 2019 (COVID-19) has infected nearly 235 million individuals and led to t ...
OCT 14, 2021
Cancer
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
OCT 14, 2021
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
Colorectal cancer develops when a series of changes occur across multiple genes.  While researchers have paid signi ...
Loading Comments...